Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May;67(5):552-8.
doi: 10.1001/archneurol.2010.76.

Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study

Ronald J Ellis  1 , Debralee Rosario, David B Clifford, Justin C McArthur, David Simpson, Terry Alexander, Benjamin B Gelman, Florin Vaida, Ann Collier, Christina M Marra, Beau Ances, J Hampton Atkinson, Robert H Dworkin, Susan Morgello, Igor Grant; CHARTER Study Group
Collaborators, Affiliations

Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study

Ronald J Ellis et al. Arch Neurol. 2010 May.

Abstract

Objective: To provide updated estimates of the prevalence and clinical impact of human immunodeficiency virus-associated sensory neuropathy (HIV-SN) and neuropathic pain due to HIV-SN in the combination antiretroviral therapy (CART) era.

Design: Prospective, cross-sectional analysis. Clinical correlates for HIV-SN and neuropathic pain, including age, exposure to CART, CD4 levels, plasma viral load, hepatitis C virus infection, and alcohol use disorders, were evaluated in univariate and multivariate models.

Setting: Six US academic medical centers.

Patients: One thousand five hundred thirty-nine HIV-infected individuals enrolled in the CNS (Central Nervous System) HIV Anti-Retroviral Therapy Effects Research study.

Main outcome measures: The presence of HIV-SN, defined by 1 or more clinical signs (diminished vibration or sharp sensation in the legs and feet; reduced ankle reflexes) in a distal, symmetrical pattern. Neuropathic pain was defined as aching, stabbing, or burning in a similar distribution. The effect on quality of life was assessed with the Medical Outcomes Study HIV Health Survey.

Results: We found HIV-SN in 881 participants. Of these, 38.0% reported neuropathic pain. Neuropathic pain was significantly associated with disability in daily activities, unemployment, and reduced quality of life. Risk factors for HIV-SN after adjustment were advancing age (odds ratio, 2.1 [95% confidence interval, 1.8-2.5] per 10 years), lower CD4 nadir (1.2 [1.1-1.2] per 100-cell decrease), current CART use (1.6 [1.3-2.8]), and past "D-drug" use (specific dideoxynucleoside analogue antiretrovirals) (2.0 [1.3-2.6]). Risk factors for neuropathic pain were past D-drug use and higher CD4 nadir.

Conclusions: Neuropathic pain and HIV-SN remain prevalent, causing substantial disability and reduced quality of life even with successful CART. The clinical correlates of HIV-SN have changed with the evolution of treatment. These findings argue for redoubled efforts to determine HIV-SN pathogenesis and the development of symptomatic and neuroregenerative therapies.

PubMed Disclaimer

Figures

Figure
Figure
Distribution of quality of life scores according to the presence and severity of neuropathic pain. The dotted line represents the median score in the Medical Outcomes Study HIV (Human Immunodeficiency Virus) Health Survey (MOS-HIV) validation sample (Wachtel et al). Boxes represent the median and interquartile range; whiskers, the 10th and 90th percentiles.
See this image and copyright information in PMC

Comment in

References

    1. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+T cell homeostasis and function in advanced HIV disease. Science. 1997;277(5322):112–116. - PubMed
    1. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS. 1997;11(12):F101–F105. - PubMed
    1. Höke A, Cornblath DR. Peripheral neuropathies in human immunodeficiency virus infection. Suppl Clin Neurophysiol. 2004;57:195–210. - PubMed
    1. Verma S, Estanislao L, Mintz L, Simpson D. Controlling neuropathic pain in HIV. Curr Infect Dis Rep. 2004;6(3):237–242. - PubMed
    1. Ellis RJ, Evans SR, Clifford DB, et al. Neurological AIDS Research Consortium. AIDS Clinical Trials Group Study Teams A5001 and A362. Clinical validation of the NeuroScreen. J Neurovirol. 2005;11(6):503–511. - PubMed

Publication types

MeSH terms

Substances